CHSJ

Curr Health Sci J, vol. 43, no. 3, 2017

Therapeutic Options in Diffuse Large B-Cell Lymphoma - A Retrospective Study and Review of the Literature

[Original Paper]

A.M. PATRASCU(1), J. NACEA(1), S. PATRASCU(2), A. GOGANAU(2), F. DELCEA(3), L. MOGOANTA(4), I. ROTARU(1)


(1)Department of Hematology, University of Medicine and Pharmacy of Craiova, Romania, 
(2)Department of Surgery, University of Medicine and Pharmacy of Craiova, Romania, 
(3)Department of Dermatology, Emergency County Hospital of Slatina, Romania, 
(4)Department of Histology, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

The aim of this retrospective study was to assess the differences between standard R-CHOP and other Rituximab-associated chemotherapy (R-miniCHOP and R-CHOEP) regimens in terms of survival and potential adverse effects. The six-month survival outcomes of 94 diffuse large B-cell lymphomas (DLBCL) patients indicated no statistical difference between overall survival and disease-free survival in the two subgroups. The biological response to therapy (blood count, LDH levels) was similar in both subgroups. Despite having different clinical indications, R-miniCHOP and R-CHOEP provide viable therapeutic alternatives to the standard R-CHOP regimen.


Keywords: diffuse large B-cell lymphoma, prognosis, CHOP, rituximab



Corresponding: S Patrascu, Department of Surgery, University of Medicine and Pharmacy of Craiova, Petru Rares St. No 2, Craiova, Romania, e-mail: stef.patrascu@gmail.com


DOI 10.12865/CHSJ.43.03.15 - Download PDF
current issue cover Download cover
Download contents

Journal archive